Blog

Non-Profit Says $850000 Gene Therapy Is At Least Twice As Expensive As It Should Be – Forbes


Forbes

Non-Profit Says $850000 Gene Therapy Is At Least Twice As Expensive As It Should Be
Forbes
Earlier this month, Spark Therapeutics announced that its gene therapy Luxturna, for a rare form of blindness, would cost $850,000 a year. The price was below the $1 million-plus price tag many had expected, and was called fair by the chief medical ...
Spark's planned price for Luxturna gene therapy for rare blindness too high: ICERReuters

Payers point to Spark's gene therapy as a model for innovative pricing plansFiercePharma
At $850000, price for new childhood blindness gene therapy four times too high, analysis saysSTAT

all 4 news articles »

Flattr this!

2018-01-12 NEWS
About Michael Zand